Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV
The most commonly reported side effects of retatrutide in clinical trials are gastrointestinal, including nausea, vomiting, diarrhoea, constipation, and decreased appetite, consistent with other GLP-1-based therapies
Patients should be advised to report suspected side effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk)
Q5- Can this be used by a pregnant or lactating mother
A clinical assessment is required to review your: BMI and current weight weight-related health conditions medical history current medicines previous weight-management treatment pregnancy plans treatment goals possible contraindications and safety risks At Private Medical Clinic, semaglutide is prescribed as part of a doctor-led treatment programme rather than offered as a standalone injection